Clémentine Sarkozy

Recent publications by Clémentine Sarkozy

1. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.Journal of Clinical Oncology · Thu,
2. Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisBlood · Tue,
3. Optimizing bridging radiotherapy prior to CAR-T cell therapy: an evidence-based approachCritical Reviews in Oncology/Hematology · Sun,
4. Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma SubtypesCancer Discovery · Fri,
5. Large B-cell lymphoma: The LYSA pragmatic guidelinesEuropean Journal of Cancer · Wed,
6. Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA GroupBlood Advances · Tue,
7. Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentBlood · Wed,
8. Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted ApproachesJournal of Clinical Oncology · Thu,
9. Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyBlood Cancer Journal · Thu,
10. Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelinesEuropean Journal of Cancer · Sat,